WAKEFIELD, Mass., Nov. 26, 2018 /CNW/ --

Total Revenue for Q3 and Nine Months 2018 Increased 289% and 247%, Respectively

Total Revenue for Q3 2018 Increased 46% Sequentially Compared to Q2 2018

On a Pro-forma Basis, Consolidated with Non-profit Entities, Revenue for Q3 and Nine Months 2018 Was $25 Million and $55 Million , Respectively

Successfully Raised Approximately US$400 Million in Oversubscribed Private Placement

Ended Q3 2018 with 29 Curaleaf Retail Locations; On Pace to Have Over 40 Locations by End of 2018 and at least 67 Locations at End of 2019

Curaleaf Holdings, Inc. (CSE: CURA) ("Curaleaf" or the "Company"), a leading vertically integrated cannabis operator in the United States, today reported its unaudited financial and operating results for the third quarter and nine months ended September 30, 2018.

"Boasting the largest retail dispensary footprint under a single, unified brand, with now 33 locations across 10 states, Curaleaf has established itself as a leader in the burgeoning U.S. cannabis industry. The expansion of our retail footprint was one of several key factors that drove significant year-over-year quarterly revenue growth of 289%, a majority of which was attributable to organic growth," said Joe Lusardi, Chief Executive Officer of Curaleaf. "With the closing of our US$400 million private placement and going-public transaction in October, we strengthened both our balance sheet and ability to accelerate our growth objectives in 2019. With a strengthened balance sheet, we are actively seeking accretive acquisitions in several major markets across the United States, including Maryland, Massachusetts, Nevada, Florida, Arizona and Connecticut. We are confident that strong organic growth, combined with a sound M&A strategy, will allow Curaleaf to establish the first national cannabis retail dispensary brand in the United States."

Financial Highlights for the Third Quarter Ended September 30, 2018

Total revenue was $21.4 million , an increase of 289%, compared to $5.5 million in Q3 2017.

, an increase of 289%, compared to in Q3 2017. Total revenue increased 47% sequentially, compared to $14.6 million in Q2 2018.

in Q2 2018. On a pro-forma basis, consolidated for non-profit entities, revenue for the third quarter was $25.0 million .

. Gross profit excluding the impact of biological assets was $13.8 million , an increase of 360%, compared to $3.0 million in Q3 2017.

, an increase of 360%, compared to in Q3 2017. Gross profit margin, excluding the impact of biological assets was 64%, compared to 55% in Q3 2017.

Adjusted EBITDA(1) loss was $5.5 million , compared to a loss of $0.2 million in Q3 2017.

, compared to a loss of in Q3 2017. Net loss was $33.7 million for the 2018 third quarter, including a $25 million one-time, non-cash, accounting entry as part of the RTO transaction and investments in new store openings and facilities, compared to a net income of $0.5 million in Q3 2017.

Financial Highlights for the Nine Months Ended September 30, 2018

Total revenue for the nine months ended September 30, 2018 was $45.1 million , an increase of 247%, compared to $13.0 million for the same period in 2017.

was , an increase of 247%, compared to for the same period in 2017. On a pro-forma basis, consolidated for non-profit entities, revenue for the first nine months of 2018 was $55.0 million .

. Gross profit excluding the impact of biological assets was $25.9 million , an increase of 275% compared to $6.9 million for the nine months ended September 30, 2018 .

, an increase of 275% compared to for the nine months ended . Gross profit margin, excluding the impact of biological assets was 57% for the nine months ended September 30, 2018 , compared to 53% in the same period the prior year.

, compared to 53% in the same period the prior year. Adjusted EBITDA(1) loss totaled $12.9 million for the nine months ended September 30, 2018 , compared to a loss of $3.5 million for the same period in 2017.

for the nine months ended , compared to a loss of for the same period in 2017. Net loss was $40.8 million for the nine months ended September 30, 2018 , which included a $25 million one-time, non-cash, accounting entry as part of the RTO transaction and investments in new store openings and facilities, compared to net loss of $3.5 million for the same period in 2017.

Year-to-Date Highlights

Industry Firsts

First cannabis company to achieve the Safe Quality Food certification under the Global Food Safety Initiative.

First cannabis company in New Jersey to formulate and sell vaporizer cartridges to patients.

to formulate and sell vaporizer cartridges to patients. First cannabis company in New York within 2017 license class to open a dispensary; three dispensaries opened year-to-date.

within 2017 license class to open a dispensary; three dispensaries opened year-to-date. First cannabis company to open drive-thru dispensary on the East Coast.

Acquisition Activity

In April, acquired Swell Farmacy, a vertically-integrated Arizona operator with four dispensaries.

operator with four dispensaries. In October, acquired Midtown Roots , the only dispensary located in the heart of downtown Phoenix, AZ.

Retail Footprint Expansion

As of September 30, 2018 , the retail footprint of Curaleaf branded dispensaries was 29 locations.

, the retail footprint of Curaleaf branded dispensaries was 29 locations. As of November 26, 2018 , there are a total of 33 locations including new stores in North Miami , Tampa and Tallahassee, Florida and a new store in downtown Phoenix, Arizona .

Capital Markets, Financing Activities and Growth Strategy

October 25, 2018 Curaleaf raised approximately US$400 million in an oversubscribed private placement offering.

Curaleaf raised approximately in an oversubscribed private placement offering. Use of proceeds:

Apply for and win new licenses, leveraging management's expertise and track record of successfully doing so through competitive application processes in strict regulatory environments.



Enter new markets through accretive acquisitions. Have already committed approximately $83.5 million to fund acquisitions in Maryland , Massachusetts , Nevada , and Arizona with an additional $83 million for minority buy-outs in Massachusetts , Florida and Connecticut .

to fund acquisitions in , , , and with an additional for minority buy-outs in , and .

Increase existing production capacity and new dispensary openings, budgeting approximately $80 million to increase cultivation and processing capacity in existing licensed states to meet expected demand and to open new dispensaries to reach the maximum number of stores permitted under licenses currently held.

to increase cultivation and processing capacity in existing licensed states to meet expected demand and to open new dispensaries to reach the maximum number of stores permitted under licenses currently held.

Increase same store sales in existing dispensaries.

October 29, 2018 completed RTO and public listing on the Canadian Securities Exchange.

Financial Results for Third Quarter Ended September 30, 2018

Total revenue for the third quarter 2018 increased 289% to $21.4 million, compared to $5.5 million in the third quarter of 2017. The increase was primarily attributable to growth in the Company's retail and wholesale segment. Revenue for the third quarter of 2018 increased 47%, compared to $14.6 million in the second quarter of 2018. Retail and wholesale revenue increased 472% to $16.6 million during the quarter, compared to $2.9 million in the third quarter of 2017. This increase was primarily driven by increased sales attributable to new retail dispensaries in Florida, New York and Massachusetts and the acquisition of Swell in April of 2018.

On a pro-forma basis, including revenue generated by non-profit entities, gross revenue for the third quarter was $25.0 million.

Total gross profit excluding the impact of biological assets for the third quarter 2018 was $13.8 million, representing a gross margin of 64%, compared to gross profit of $3.0 million and a gross margin of 55% in the third quarter of 2017. As Curaleaf continues to grow its business and achieve scale particularly in limited license markets, including Florida, New York, Maryland and Massachusetts, the Company expects its gross profits margin to expand meaningfully in 2019.

Adjusted EBITDA(1) loss was $5.5 million for the 2018 third quarter, compared to a loss of $0.2 million for the third quarter of 2017.

Net loss for the third quarter 2018 was $33.7 million, compared to net income of $0.5 million in the third quarter of 2017. The increase in net loss was primarily driven by a $25 million one-time, non-cash, accounting entry as part of the RTO transaction and investments in new stores openings and facilities.

Financial Results for the Nine Months Ended September 30, 2018

Total revenue for the nine months ended September 30, 2018 increased 247% to $45.1 million, compared to $13 million in the same period of 2017. Increased revenues are primarily attributable to growth in the Company's retail and wholesale segment. Retail and wholesale revenue increased 463% to $33.8 million during the nine months ended September 30, 2018, compared to $6 million in the same period of 2017. This is primarily driven by increased sales from the opening of new retail dispensary and production facilities.

Total gross profit excluding the impact of biological assets for the nine months ended September 30, 2018 was $25.9 million, representing a total gross margin of 57%, compared to gross profit of $6.9 million and a gross margin of 53% in the same period of 2017.

Adjusted EBITDA(1) loss was $12.9 million for the nine months ended September 30, 2018 due to forward spending on cultivation and manufacturing capacity, dispensary openings and increased marketing activities.

Net loss for the nine months ended September 30, 2018 was $40.8 million, compared to a net loss of $3.5 million in the same period of 2017. The increase in net loss was again, primarily driven by a one-time, non-cash, accounting entry as part of the RTO transaction and investments including new stores openings and facilities.

Balance Sheet and Liquidity

As of September 30, 2018, the Company had $48 million of cash.

On October 29, 2018, the Company received net proceeds of approximately $380 million from the completion of its private placement offering. As of today, the Company has approximately $320 million in cash after paying an aggregate of $65m for the minority buyouts in Florida and Connecticut of $25 million and $40 million respectively.

As of October 25, 2018, total common shares were 457,635,788, of which 335,465,083 are subordinated voting shares and 122,170,705 are multiple voting shares. Fully diluted, the Company has 508,120,208 shares outstanding.

Outlook for Full Year 2019

For the full year 2019, Curaleaf estimates revenue of $400 million enterprise wide, including revenue generated by the non-profits, and free cash flow of $100 million. The Company anticipates completing two acquisitions in the fourth quarter of 2018 in Maryland and Massachusetts. At the end of 2018, Curaleaf anticipates at least 40 operational stores.

The guidance for fiscal 2019 are based on a number of assumptions, including:

The successful execution and implementation of a business strategy that allows the Company to increase its footprint to at least 67 retail stores by the end of 2019.

Increase same store sales at existing retail dispensaries.

Expansion of current cultivation and manufacturing capacity.

Receiving the appropriate regulatory approvals that allow the Company to enter at least two additional states.

Continued forward momentum of the regulatory landscape in the United States .

. The absence of a significant shift in economic conditions or material changes in the retail competitive environment.

(1) See "Non-IFRS Financial and Performance Measures" below for more information regarding Curaleaf's use of Non-IFRS financial measures.

Consolidated Financial Statements and Management's Discussion and Analysis

The Company's unaudited consolidated interim financial statements and accompanying notes as at and for the three and nine months ended September 30, 2018 are available under the Company's profile on SEDAR at www.sedar.com and on the Investor Relations section of the Company's website at ir.curaleaf.com.

Conference Call and Webcast Information

Curaleaf will host a conference call and audio webcast on Monday, November 26th at 4:30 p.m. EST to answer questions about the Company's operational and financial highlights. The dial-in numbers for the conference call are +1-877-407-9039 (U.S. Toll-Free) or +1-201-689-8470 (International). Please dial-in 10 to 15 minutes prior to the start time of the conference call and an operator will register your name and organization.

The conference call will also be available via webcast, which can be accessed through the Investor Relations section of Curaleaf's website, https://ir.curaleaf.com/ir-calendar.

For interested individuals unable to join the conference call, a dial-in replay of the call will be available until December 10, 2018 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 13684909. The online archive of the webcast will be available on https://ir.curaleaf.com/ir-calendar for 30 days following the call.

About Curaleaf Holdings, Inc.

Curaleaf Holdings, Inc. is the parent of Curaleaf, Inc., a leading vertically integrated cannabis operator in the United States. Headquartered in Wakefield, Massachusetts, Curaleaf, Inc. has a presence in 12 states. Curaleaf, Inc. operates 33 dispensaries, 12 cultivation sites and 10 processing sites with a focus on highly populated, limited license states, including Florida, Massachusetts, New Jersey and New York. Curaleaf, Inc. leverages its extensive research and development capabilities to distribute cannabis products in multiple formats with the highest standard for safety, effectiveness, consistent quality and customer care. Curaleaf is committed to being the industry's leading resource in education and advancement through research and advocacy. Curaleaf Inc.'s Florida operations were the first in the cannabis industry to receive the Safe Quality Food certification under the Global Food Safety Initiative, setting a new standard of excellence.

For more information please visit www.curaleaf.com.

Non-IFRS Financial and Performance Measures

In this press release Curaleaf refers to certain non-IFRS financial measures such as Adjusted EBITDA, being Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) less certain non-cash equity compensation expense, including one-time transaction fees and all other non-cash items. These measures do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other issuers.

Adjusted EBITDA loss for the three-month period of $5.5 million is calculated as the Company's loss from operations of $6.8 million less Depreciation and amortization of $1.3 million. For the nine-month period, adjusted EBITDA loss of $12.9 million is calculated as the Company's loss from operations of $16.7 million less Depreciation and amortization of $3.8 million.

Forward Looking Information

Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, many of which, by their nature, are inherently uncertain and outside of the Company's control and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "will", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include, but are not limited to, information concerning the ability of the Company to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors. Those assumptions and factors are based on information currently available to the Company. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: the ability of the Company to develop the Company's brand and meet its growth objectives, the ability of the Company to complete acquisitions that are accretive to the Company's revenue, the ability of the Company to obtain and/or maintain licenses to operate in the jurisdictions in which it operates or in which it expects or plans to operate. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking statements and forward-looking information. The forward-looking information contained in this release is made as of the date hereof and the Company assumes no obligation to update or revise any forward-looking statements or forward-looking information that are incorporated by reference herein, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.

Company Contact:

Curaleaf Holdings, Inc.

Christine Rigby, SVP, Investor Relations

PH: (781) 451-0145

[email protected]

Investor Contact:

KCSA Strategic Communications

Valter Pinto, Managing Director

PH: (212) 896-1260

[email protected]

Media Contact:

KCSA Strategic Communications

Anne Donohoe, Managing Director

PH: (347) 487-6199

[email protected]

Curaleaf, Inc. Condensed Interim Consolidated Statements of Financial Position Unaudited (In thousands, except for share and per share amounts)





September 30,

December 31,



2018

2017 Assets











Current assets:











Cash

$ 48,050

$ 20,975 Accounts receivable



3,592



1,246 Inventory



22,029



12,661 Biological assets



2,385



1,439 Prepaid expenses and other current assets



2,043



844 Total current assets



78,099



37,165 Property and equipment



48,901



23,519 Notes receivable



29,107



21,051 Intangible assets, net



47,252



27,223 Goodwill



39,599



31,561 Investments



4,667



3,754 Other assets



5,485



5,278 Total assets

$ 253,110

$ 149,551













Liabilities and Shareholders' Equity











Current liabilities:











Accounts payable

$ 5,368

$ 1,720 Accrued taxes



3,347



827 Accrued expenses



6,137



2,246 Non-controlling interest contingency and buyout



68,099



— Convertible note



32,716



— Total current liabilities



115,667



4,793 Deferred tax liability



1,822



1,453 Notes payable – net of current portion



80,098



1,872 Notes payable – related party, net of current portion



2,403



8,322 Non-controlling interest contingency



—



28,346 Total liabilities



199,990



44,786













Shareholders' equity:











Share capital



137,406



109,855 Treasury shares



(3,466)



(966) Reserves



13,788



5,404 Accumulated deficit



(49,733)



(8,899) Total Curaleaf, Inc. shareholders' equity



97,995



105,394 Redeemable non-controlling interest contingency and buyout



(68,099)



(28,346) Non-controlling interest contingency



—



1,335 Redeemable non-controlling interest



23,224



26,382 Total shareholders' equity



53,120



104,765 Total liabilities and shareholders' equity

$ 253,110

$ 149,551

Curaleaf, Inc. Condensed Interim Consolidated Statements of Profit and Loss Unaudited (In thousands, except for share and per share amounts)





Three Months Ended

Nine Months Ended



September 30,

September 30,



2018

2017

2018

2017 Revenues:























Retail and wholesale revenue

$ 16,625

$ 2,868

$ 33,801

$ 6,002 Management fee income



4,745



2,678



11,295



7,029 Total revenues



21,370



5,546



45,096



13,031 Cost of goods sold



12,420



3,517



28,447



8,089 Increase in fair value of biological assets



5,085



2,679



11,041



4,226 Gross profit



14,035



4,708



27,690



9,168 Operating expenses:























Salaries and benefits



7,713



2,025



16,971



4,698 Sales and marketing



1,047



781



2,319



1,474 Rent and occupancy



2,246



38



4,289



401 Travel



973



225



2,269



715 Professional fees



4,966



923



8,774



2,765 General and administrative



2,664



302



4,840



735 Depreciation and amortization



1,271



841



3,796



2,213 Share-based compensation



(28)



658



1,133



1,889 Total operating expenses



20,852



5,793



44,391



14,890 Loss from operations



(6,817)



(1,085)



(16,701)



(5,722) Other income (expense)



20



—



20



— Interest income



1,163



2,421



3,123



3,905 Interest expense



(2,124)



(1,311)



(2,953)



(1,805) Loss on change in FV on convertible note



(25,100)



—



(25,100)



— Total other income (expense), net



(26,041)



1,110



(24,910)



2,100 Income (loss) before provision for income taxes



(32,858)



25



(41,611)



(3,622) Income tax recovery (expense)























Current



(2,515)



133



(3,347)



(1,613) Deferred, net



(189)



—



(369)



— Net Income (loss) and comprehensive income (loss)



(35,562)



158



(45,327)



(5,235) Less: Net income (loss) attributable to redeemable non-controlling interest



(1,889)



(301)



(4,493)



(1,731) Net income (loss) attributable to Curaleaf, Inc.

$ (33,673)

$ 459

$ (40,834)

$ (3,504) Basic net income (loss) per share attributable to Curaleaf, Inc.

$ (2.86)

$ 0.05

$ (3.49)

$ (0.36) Diluted net income (loss) per share attributable to Curaleaf, Inc.

$ (2.86)

$ 0.04

$ (3.49)

$ (0.36) Weighted average common shares outstanding—basic



11,793,172



9,724,007



11,714,165



9,701,885 Weighted average common shares outstanding—diluted



11,793,172



10,236,609



11,714,165



9,701,885

























Reconciliation to adjusted EBITDA

















































Loss from operations



(6,817)



(1,085)



(16,701)



(5,722) Less depreciation and amortization



1,271



841



3,796



2,213 Adjusted EBITDA



(5,546)



(244)



(12,905)



(3,509)

SOURCE Curaleaf, Inc.

Related Links

https://www.curaleaf.com

